Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

2,285

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

2,285 results for “T-cells”

Learn how ShareScore rates datasets ↗
zenodo28/100

Dataset #2 related to article "NaCl enhances CD8+ T-cell effector functions in cancer immunotherapy"

<p><span>CD8<sup>+</sup> T cells control tumors but inevitably become dysfunctional. Ionic metabolism is emerging as a regulator of CD8<sup>+</sup> T cells in anti-tumor immunity. We show that sodium chloride (NaCl) counteracts T-cell dysfunction to promote cancer regression. NaCl supplementation during CD8<sup>+</sup> T-cell culture induced potent effector differentiation, IFN-</span><span>g</span><span> production and cytotoxicity while maintaining gene networks responsible for stem-like plasticity. Accordingly, adoptive transfer of tumor-specific T cells resulted in superior anti-tumor immunity in a humanized model. In mice, high-salt diet reduced growth of experimental tumors in a CD8<sup>+</sup> T cell-dependent manner, by inhibiting terminal differentiation, and by enhancing the effector potency of CD8<sup>+</sup> T cells. Mechanistically, NaCl enhanced glutamine consumption that was critical for transcriptional, epigenetic and functional reprogramming. In humans, CD8<sup>+</sup> T cells undergoing antigen recognition in tumors and predicting favorable response to checkpoint blockade immunotherapy resembled those induced by NaCl. Thus, NaCl metabolism is a major regulator of CD8<sup>+</sup> T-cell effector function, with potential translation in cancer immunotherapy.</span></p>

openMay 2024View details →
zenodo28/100

Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution - raw data

<p><strong><em>sample_id</em>.h5</strong></p> <ul> <li>Feature-barcode matrix (<em>filtered_feature_bc_matrix.h5</em>, 10x-Genomics-formatted hdf5 file) for indicated sample.</li> </ul> <p><strong><em>sample_id</em>-VDJ.csv</strong></p> <ul> <li><em>filtered_contig_annotations.csv</em> file for indicated sample.</li> </ul> <p><strong>sample-metadata.csv</strong></p> <ul> <li>Metadata for each sample: donor_id (donor of origin), sort (sorting strategy), batch (sequencing batch).</li> </ul> <p>&nbsp;</p>

restrictedcc-by-4.0Aug 2024View details →
zenodo28/100

CAR T-cell therapy

SciDraw upload

opencc-by-4.0Aug 2024View details →
zenodo28/100

Dataset #1 related to article "NaCl enhances CD8+ T-cell effector functions in cancer immunotherapy"

<p><span>CD8<sup>+</sup> T cells control tumors but inevitably become dysfunctional. Ionic metabolism is emerging as a regulator of CD8<sup>+</sup> T cells in anti-tumor immunity. We show that sodium chloride (NaCl) counteracts T-cell dysfunction to promote cancer regression. NaCl supplementation during CD8<sup>+</sup> T-cell culture induced potent effector differentiation, IFN-</span><span>g</span><span> production and cytotoxicity while maintaining gene networks responsible for stem-like plasticity. Accordingly, adoptive transfer of tumor-specific T cells resulted in superior anti-tumor immunity in a humanized model. In mice, high-salt diet reduced growth of experimental tumors in a CD8<sup>+</sup> T cell-dependent manner, by inhibiting terminal differentiation, and by enhancing the effector potency of CD8<sup>+</sup> T cells. Mechanistically, NaCl enhanced glutamine consumption that was critical for transcriptional, epigenetic and functional reprogramming. In humans, CD8<sup>+</sup> T cells undergoing antigen recognition in tumors and predicting favorable response to checkpoint blockade immunotherapy resembled those induced by NaCl. Thus, NaCl metabolism is a major regulator of CD8<sup>+</sup> T-cell effector function, with potential translation in cancer immunotherapy.</span></p>

openOct 2023View details →
ClinicalTrials.gov28/100

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

ClinicalTrials.gov study NCT05934448. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

ClinicalTrials.gov study NCT00091559. IPD Sharing: Not stated. Countries: 0. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Pat

ClinicalTrials.gov study NCT00629798. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

ClinicalTrials.gov study NCT01841021. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

ClinicalTrials.gov study NCT02390739. IPD Sharing: Not stated. Countries: 0. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Role of T-Cells in Asthma

ClinicalTrials.gov study NCT00001408. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

ClinicalTrials.gov study NCT06066346. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

ClinicalTrials.gov study NCT00217425. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

ClinicalTrials.gov study NCT06623396. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

ClinicalTrials.gov study NCT01007448. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

ClinicalTrials.gov study NCT01626664. IPD Sharing: Not stated. Countries: 6. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

ClinicalTrials.gov study NCT07249528. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic M

ClinicalTrials.gov study NCT07052370. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (

ClinicalTrials.gov study NCT03709706. IPD Sharing: YES. Countries: 5. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

ClinicalTrials.gov study NCT02737046. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

ClinicalTrials.gov study NCT02273739. IPD Sharing: Not stated. Countries: 2. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record